Latest period
$52.06B
YoY change
+9.4%
5Y CAGR
+9.7%
Peak year (2025)
$52.13B
Latest annual
$52.13B
Total Equity history chart for Abbott Laboratories (ABT) from 1985 to 2025
Latest: $52.13B
Total Equity growth chart for Abbott Laboratories (ABT) from 1985 to 2025
Latest: +9.4%
Total Equity history table for Abbott Laboratories (ABT) from 1985 to 2025
| 2025 | $52.13B | +9.4% | +$4.47B | ||
| 2024 | $47.66B | +23.5% | +$9.06B | ||
| 2023 | $38.60B | +5.2% | +$1.92B | ||
| 2022 | $36.69B | +2.5% | +$884.00M | ||
| 2021 | $35.80B | +9.2% | +$3.02B | ||
| 2020 | $32.78B | +5.5% | +$1.70B | ||
| 2019 | $31.09B | +1.8% | +$564.00M | ||
| 2018 | $30.52B | -1.2% | −$373.00M | ||
| 2017 | $30.90B | +50.4% | +$10.36B | ||
| 2016 | $20.54B | -3.2% | −$673.00M | ||
| 2015 | $21.21B | -1.5% | −$315.00M | ||
| 2014 | $21.53B | -14.5% | −$3.65B | ||
| 2013 | $25.17B | -5.8% | −$1.55B | ||
| 2012 | $26.72B | +9.3% | +$2.28B | ||
| 2011 | $24.44B | +7.8% | +$1.76B | ||
| 2010 | $22.68B | -2.0% | −$467.49M | ||
| 2009 | $23.14B | +32.4% | +$5.66B | ||
| 2008 | $17.48B | -1.7% | −$298.99M | ||
| 2007 | $17.78B | +26.5% | +$3.72B | ||
| 2006 | $14.05B | -2.5% | −$361.08M | ||
| 2005 | $14.42B | +0.6% | +$89.49M | ||
| 2004 | $14.33B | +9.6% | +$1.25B | ||
| 2003 | $13.07B | +22.6% | +$2.41B | ||
| 2002 | $10.66B | +17.7% | +$1.61B | ||
| 2001 | $9.06B | +5.7% | +$488.53M | ||
| 2000 | $8.57B | +15.4% | +$1.14B | ||
| 1999 | $7.43B | +30.0% | +$1.71B | ||
| 1998 | $5.71B | +14.3% | +$714.98M | ||
| 1997 | $5.00B | +3.7% | +$178.50M | ||
| 1996 | $4.82B | +9.6% | +$423.33M | ||
| 1995 | $4.40B | +8.6% | +$347.45M | ||
| 1994 | $4.05B | +10.2% | +$374.47M | ||
| 1993 | $3.67B | +9.8% | +$327.33M | ||
| 1992 | $3.35B | +4.5% | +$144.60M | ||
| 1991 | $3.20B | +13.0% | +$369.40M | ||
| 1990 | $2.83B | +3.9% | +$107.20M | ||
| 1989 | $2.73B | +10.6% | +$261.80M | ||
| 1988 | $2.46B | +17.7% | +$371.10M | ||
| 1987 | $2.09B | +17.7% | +$314.60M | ||
| 1986 | $1.78B | -4.9% | −$91.80M | ||
| 1985 | $1.87B | — | — |
- 2025$52.13B+9.4%
- 2024$47.66B+23.5%
- 2023$38.60B+5.2%
- 2022$36.69B+2.5%
- 2021$35.80B+9.2%
- 2020$32.78B+5.5%
- 2019$31.09B+1.8%
- 2018$30.52B-1.2%
- 2017$30.90B+50.4%
- 2016$20.54B-3.2%
- 2015$21.21B-1.5%
- 2014$21.53B-14.5%
- 2013$25.17B-5.8%
- 2012$26.72B+9.3%
- 2011$24.44B+7.8%
- 2010$22.68B-2.0%
- 2009$23.14B+32.4%
- 2008$17.48B-1.7%
- 2007$17.78B+26.5%
- 2006$14.05B-2.5%
- 2005$14.42B+0.6%
- 2004$14.33B+9.6%
- 2003$13.07B+22.6%
- 2002$10.66B+17.7%
- 2001$9.06B+5.7%
- 2000$8.57B+15.4%
- 1999$7.43B+30.0%
- 1998$5.71B+14.3%
- 1997$5.00B+3.7%
- 1996$4.82B+9.6%
- 1995$4.40B+8.6%
- 1994$4.05B+10.2%
- 1993$3.67B+9.8%
- 1992$3.35B+4.5%
- 1991$3.20B+13.0%
- 1990$2.83B+3.9%
- 1989$2.73B+10.6%
- 1988$2.46B+17.7%
- 1987$2.09B+17.7%
- 1986$1.78B-4.9%
- 1985$1.87B—
Total Equity values are taken from Abbott Laboratories's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Abbott Laboratories (ABT)
According to Abbott Laboratories's latest reported financial statements, the company's latest reported total equity is $52.06B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Abbott Laboratories (ABT) reported total equity of $52.13B – grew 9.4% year-over-year.
Abbott Laboratories total equity compound annual growth for the 2020–2025 (5 years) window is +9.7%, sustaining 7 straight years of year-over-year growth.
The highest annual total equity of $52.13B was reported in 2025. The lowest in the available history was $1.78B in 1986.
Abbott Laboratories Total Equity by Year
Abbott Laboratories Total Equity 2025: $52.13B
Abbott Laboratories posted total equity of $52.13B in 2025, grew 9.4% from 2024. This figure represents the highest annual value in the available history.
Abbott Laboratories Total Equity 2024: $47.66B
In 2024, Abbott Laboratories reported total equity of $47.66B, grew 23.5% from 2023.
Abbott Laboratories Total Equity 2023: $38.60B
Abbott Laboratories total equity in 2023 was $38.60B, grew 5.2% from 2022.
Abbott Laboratories Total Equity 2022: $36.69B
2022's total equity for Abbott Laboratories came in at $36.69B, edged up 2.5% from 2021.
Abbott Laboratories Total Equity 2021: $35.80B
Abbott Laboratories total equity in 2021 was $35.80B.
See more financial history for Abbott Laboratories (ABT).
Sector peers by Total Equity
Healthcare peers of Abbott Laboratories (ABT), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation